Michael Thomas Heffernan
CIK 1448914 · Chairman, President and CEO · last filed 2026-09-17
Michael Thomas Heffernan is a Chairman, President and CEO who has filed 123 SEC Form 4 insider transactions across 12 companies since 2008. The most recent filing, for TRVI, was dated Sep 17, 2026. Across all open-market trades the lifetime net is −$26.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.3M across reported positions. 8 SEC filings were submitted jointly with Biohaven Pharmaceutical Holding Co Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
COLL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1500 LIBERTY RIDGE DRIVE, SUITE 321
WAYNE, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Director | 6,351 | $12.51 | $79.5K | -$569.2K | 11 | 2026-09-17 |
| ENGNW | Director | — | $0.23 | — | $0 | 2 | 2026-06-17 |
| AVTX | Director | — | $6.77 | — | $0 | 3 | 2026-06-04 |
| BHVN | Director | 15,178 | $14.45 | $219.3K | $0 | 11 | 2025-05-07 |
| COLL | Director | 213,371 | $23.21 | $4.95M | -$15.14M | 17 | 2025-02-12 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | — | $0.69 | — | $0 | 4 | 2023-06-26 |
| AKBA | Director | 48,586 | $0.64 | $31.3K | $0 | 4 | 2021-06-03 |
| COLLEGIUM PHARMACEUTICAL, INC (ESPR) Delisted | Director | 126,623 | $3.18 | $402.7K | -$10.59M | 31 | 2019-08-13 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 4 | 2018-12-13 |
| Ocata Therapeutics, Inc. (OCAT) Delisted | Director | 0 | — | — | $0 | 7 | 2016-02-11 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | Director | — | $1.95 | — | $0 | 7 | 2014-02-04 |
| CORNERSTONE THERAPEUTICS INC (CRTXD) Delisted | Director | — | — | — | $0 | 1 | 2008-11-04 |
Recent Filings
123 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-17 | TRVI | Mixed | +100 | -$468.1K | EDGAR |
| 2026-09-15 | TRVI | Notice (144) | −39,473 | -$627.2K | EDGAR |
| 2026-06-17 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2026-06-04 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-04 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-07-10 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2025-07-09 | COLL | Notice (144) | −10,328 | -$332.3K | EDGAR |
| 2025-07-08 | COLL | Notice (144) | −790 | -$24.8K | EDGAR |
| 2025-07-07 | COLL | Notice (144) | −14,210 | -$444.1K | EDGAR |
| 2025-07-02 | COLL | Notice (144) | −25,000 | -$757.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.